Autoimmune
Four Ways to Kill a B-Cell: Why In Vivo CAR-T Just Became Biotech's Hottest Autoimmune Bet
In vivo CAR-T just became biotech's hottest autoimmune bet: $14B committed, zero human readouts. We break down all four B-cell depletion modalities, the leaders, the risks, and what's buyable.